SOURCE: PetLife Pharmaceuticals, Inc.
BEVERLY HILLS, CA--(Marketwired - Aug 13, 2014) - PetLife Pharmaceuticals, Inc. (PINKSHEETS: EVGI) (PINKSHEETS: EVGID) today announced it has launched its new website at: www.petlifepharma.com.
The website contains information about the research and science of the Company's newly launched product, Escozine for Pets™, as well as an online e-commerce engine and comprehensive information of interest to investors, veterinarians and pet owners.
PetLife recent announced it has closed a transaction and become a fully reporting, publicly traded company.
About PetLife Pharmaceuticals
PetLife is a registered US Veterinary Pharmaceutical company, incorporated in 2012, and is a spinoff of Medolife Corp.
PetLife has developed and is launching a new generation of high potency veterinary cancer medications and nutraceuticals for companion pets. It is based on the same patented 'Escozine for humans' formula that has been sold by affiliate Medolife in 40 countries -- using a patented polarization technology that potentiates the main ingredients to dramatically increase their effectiveness.
PetLife's mission is to bring its new, scientifically proven, non-toxic, potentiated bioactive nutraceuticals and prescription medication to the world of veterinary oncology -- with the ultimate goal of preventing cancer, extending the life of pets suffering from cancer while improving their quality of life. In the US alone, consumer spending on domestic companion animals is expected to reach over $58 billion in 2014 with over $13 billion being spent on over the counter medications.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: PetLife encourages those interested in our Company to rely only on information included in our filings with the United States Securities and Exchange Commission which can be found at www.sec.gov. Statements released by the Company, that are not purely historical are forward-looking within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the company's expectations, hopes, intentions, and strategies for the future. Investors are cautioned that forward-looking statements involve risk and uncertainties that may affect the company's business prospects and performance. The Company's actual results could differ materially from those in such forward-looking statements. Risk factors include but are not limited to general economic, competitive, governmental, and technological factors as discussed in the company's filings with the SEC on Forms 10-K, 10-Q, and 8-K. The Company does not undertake any responsibility to update the forward-looking statements contained in this release.